Effect of platelet-rich plasma therapy in rheumatoid arthritis

Comparison of the Effectiveness of Platelet-Rich Plasma (PRP) Therapy with Steroid Therapy in Improving the Clinical Symptoms of Patients with Rheumatoid Arthritis.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221203056694N1

Enrollment

Registered

2023-01-28

Start date

2023-01-21

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis (RA). Other rheumatoid arthritis

Interventions

Intervention 1: Intervention group: Platelet-rich plasma (PRP) therapy uses injections of a concentration of a patient’s own platelets to accelerate the healing of injured tendons, ligaments, and join

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: This study will be done on 40 patients with RA diseases who were diagnosed at the rheumatology clinic of Hafez Hospital, according to the American College of Rheumatology/European League Against Rheumatism criteria.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Erythrocyte Sedimentation Rate (ESR). Timepoint: Before and after Platelet-rich plasma (PRP) therapy. Method of measurement: Westergren method.;C-reactive protein (CRP). Timepoint: Before and after Platelet-rich plasma (PRP) therapy. Method of measurement: ELISA.;Anti Citrullinated peptide Antibody. Timepoint: Before and after Platelet-rich plasma (PRP) therapy. Method of measurement: ELISA.;Antinuclear Antibody (ANA). Timepoint: Before and after Platelet-rich plasma (PRP) therapy. Method of measurement: ELISA.;Rheumatoid Arthritis (RA) factor. Timepoint: Before and after Platelet-rich plasma (PRP) therapy. Method of measurement: ELISA.;Interleukin-1 beta. Timepoint: Before and after Platelet-rich plasma (PRP) therapy. Method of measurement: ELISA.;Radiological Examination. Timepoint: Before and after Platelet-rich plasma (PRP) therapy. Method of measurement: Radiology.	—

Measure

Time frame

Erythrocyte Sedimentation Rate (ESR). Timepoint: Before and after Platelet-rich plasma (PRP) therapy. Method of measurement: Westergren method.;C-reactive protein (CRP). Timepoint: Before and after Platelet-rich plasma (PRP) therapy. Method of measurement: ELISA.;Anti Citrullinated peptide Antibody. Timepoint: Before and after Platelet-rich plasma (PRP) therapy. Method of measurement: ELISA.;Antinuclear Antibody (ANA). Timepoint: Before and after Platelet-rich plasma (PRP) therapy. Method of measurement: ELISA.;Rheumatoid Arthritis (RA) factor. Timepoint: Before and after Platelet-rich plasma (PRP) therapy. Method of measurement: ELISA.;Interleukin-1 beta. Timepoint: Before and after Platelet-rich plasma (PRP) therapy. Method of measurement: ELISA.;Radiological Examination. Timepoint: Before and after Platelet-rich plasma (PRP) therapy. Method of measurement: Radiology.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNasser Gholijani

Shiraz University of Medical Sciences

gholijanin@sums.ac.ir+98 71 3208 4176

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026